Skip to main content
Top
Published in: Digestive Diseases and Sciences 7/2022

Open Access 28-06-2021 | Coronavirus | Original Article

Impact of the Coronavirus Disease Pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease

Authors: Emma Paulides, Annelieke Pasma, Nicole S. Erler, Rachel L. A. van Eijk, Annemarie C. de Vries, C. Janneke van der Woude

Published in: Digestive Diseases and Sciences | Issue 7/2022

Login to get access

Abstract

Background

To learn from the crisis caused by the coronavirus disease (COVID-19) pandemic and be prepared for future pandemics, it is important to investigate the impact of this period on the wellbeing of patients with inflammatory bowel disease (IBD).

Aims

To describe the health-related quality of life (HRQoL) and disease control of IBD patients during the first wave of the COVID-19 pandemic in The Netherlands.

Methods

Between March 17 and July 1, 2020, patients aged 18 years and older with IBD from the Erasmus MC (Rotterdam, The Netherlands) were invited to complete online questionnaires at week 0, 2, 6 and 12. The Inflammatory Bowel Disease Questionnaire (IBDQ), the Inflammatory Bowel Disease Control-8 (IBD-control-8) and the numeric rating scale on fatigue were used. The evolution of the different outcomes over time was measured using mixed models.

Results

Of 1151 invited patients, 851 patients (67% CD and 33% UC or IBD-U) participated in the study (response rate 74%). No relevant changes in total scores were found over time for the IBDQ (effect estimate 0.006, 95% CI [− 0.003 to 0.015]) and IBD-control-8 (effect estimate 0.004, 95% CI [0.998–1.011]). There was a slight, increasing trend in fatigue scores over time (effect estimate 0.011, 95% CI [0.004, 0.019]).

Conclusions

This first lock down due to the COVID-19 pandemic in The Netherlands did not impact on the HRQoL and disease control of patients with IBD. Up to date information may have contributed to a stable HRQoL in IBD patients even in an extreme period with restrictions and insecurities.
Appendix
Available only for authorised users
Literature
1.
go back to reference Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–1720.CrossRef Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–1720.CrossRef
2.
go back to reference Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.CrossRef Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.CrossRef
4.
go back to reference Bussani R, Schneider E, Zentilin L et al. Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. EBioMedicine. 2020;61:103104.CrossRef Bussani R, Schneider E, Zentilin L et al. Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. EBioMedicine. 2020;61:103104.CrossRef
5.
go back to reference Carsana L, Sonzogni A, Nasr A et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020;20:1135–1140.CrossRef Carsana L, Sonzogni A, Nasr A et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020;20:1135–1140.CrossRef
7.
go back to reference de Haas M, Faber R. Hamersma M. How COVID-19 and the Dutch ‘intelligent lockdown’ change activities, work and travel behaviour: Evidence from longitudinal data in the Netherlands. Transp Res Interdiscip Perspect 2020;6:100150.PubMedPubMedCentral de Haas M, Faber R. Hamersma M. How COVID-19 and the Dutch ‘intelligent lockdown’ change activities, work and travel behaviour: Evidence from longitudinal data in the Netherlands. Transp Res Interdiscip Perspect 2020;6:100150.PubMedPubMedCentral
8.
go back to reference Torres J, Mehandru S, Colombel JF et al. Crohn’s disease. Lancet. 2017;389:1741–1755.CrossRef Torres J, Mehandru S, Colombel JF et al. Crohn’s disease. Lancet. 2017;389:1741–1755.CrossRef
9.
go back to reference Ungaro R, Mehandru S, Allen PB et al. Ulcerative colitis. Lancet. 2017;389:1756–1770.CrossRef Ungaro R, Mehandru S, Allen PB et al. Ulcerative colitis. Lancet. 2017;389:1756–1770.CrossRef
10.
go back to reference Sheriff MZ, Mansoor E, Luther J et al. Opportunistic infections are more prevalent in Crohn’s disease and ulcerative colitis: a large population-based study. Inflamm Bowel Dis. 2020;26:291–300.CrossRef Sheriff MZ, Mansoor E, Luther J et al. Opportunistic infections are more prevalent in Crohn’s disease and ulcerative colitis: a large population-based study. Inflamm Bowel Dis. 2020;26:291–300.CrossRef
11.
go back to reference An P, Ji M, Ren H et al. Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan. China. Lancet Gastroenterol Hepatol. 2020;5:525–527.CrossRef An P, Ji M, Ren H et al. Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan. China. Lancet Gastroenterol Hepatol. 2020;5:525–527.CrossRef
12.
go back to reference Monteleone G, Ardizzone S. Are patients with inflammatory bowel disease at increased risk for covid-19 infection? J Crohns Colitis. 2020;14:1334–1336.CrossRef Monteleone G, Ardizzone S. Are patients with inflammatory bowel disease at increased risk for covid-19 infection? J Crohns Colitis. 2020;14:1334–1336.CrossRef
13.
go back to reference Knowles SR, Graff LA, Wilding H et al. Quality of life in inflammatory bowel disease: A systematic review and meta-analyses-part I. Inflamm Bowel Dis. 2018;24:742–751.CrossRef Knowles SR, Graff LA, Wilding H et al. Quality of life in inflammatory bowel disease: A systematic review and meta-analyses-part I. Inflamm Bowel Dis. 2018;24:742–751.CrossRef
14.
go back to reference Mikocka-Walus A, Knowles SR, Keefer L et al. Controversies revisited: A systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. Inflamm Bowel Dis. 2016;22:752–762.CrossRef Mikocka-Walus A, Knowles SR, Keefer L et al. Controversies revisited: A systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. Inflamm Bowel Dis. 2016;22:752–762.CrossRef
15.
go back to reference Gracie DJ, Hamlin PJ, Ford AC. The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment. Lancet Gastroenterol Hepatol. 2019;4:632–642.CrossRef Gracie DJ, Hamlin PJ, Ford AC. The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment. Lancet Gastroenterol Hepatol. 2019;4:632–642.CrossRef
16.
go back to reference Brooks SK, Webster RK, Smith LE et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020;395:912–920.CrossRef Brooks SK, Webster RK, Smith LE et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020;395:912–920.CrossRef
17.
go back to reference Irvine EJ. Development and subsequent refinement of the inflammatory bowel disease questionnaire: A quality-of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1999;28:S23-27.CrossRef Irvine EJ. Development and subsequent refinement of the inflammatory bowel disease questionnaire: A quality-of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1999;28:S23-27.CrossRef
18.
go back to reference Guyatt G, Mitchell A, Irvine EJ et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96:804–810.CrossRef Guyatt G, Mitchell A, Irvine EJ et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96:804–810.CrossRef
19.
go back to reference Bodger K, Ormerod C, Shackcloth D et al. Development and validation of a rapid, generic measure of disease control from the patient’s perspective: the IBD-control questionnaire. Gut. 2014;63:1092–1102.CrossRef Bodger K, Ormerod C, Shackcloth D et al. Development and validation of a rapid, generic measure of disease control from the patient’s perspective: the IBD-control questionnaire. Gut. 2014;63:1092–1102.CrossRef
20.
go back to reference Minnock P, Kirwan J, Bresnihan B. Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1533–1536.CrossRef Minnock P, Kirwan J, Bresnihan B. Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1533–1536.CrossRef
22.
go back to reference Bates D, Mächler M, Bolker B et al. Fitting linear mixed-effects models using lme4. J Stat Softw 2015;67:48. CrossRef Bates D, Mächler M, Bolker B et al. Fitting linear mixed-effects models using lme4. J Stat Softw 2015;67:48. CrossRef
24.
go back to reference Mollie E, Brooks KK, van Benthem KJ, Magnusson A, Berg CW, Nielsen A, Skaug HJ, Mächler M, Bolker BM. glmmTMB balances speed and flexibility among packages for zero-inflated generalized linear mixed modeling. R J 2017;2017:378–400. Mollie E, Brooks KK, van Benthem KJ, Magnusson A, Berg CW, Nielsen A, Skaug HJ, Mächler M, Bolker BM. glmmTMB balances speed and flexibility among packages for zero-inflated generalized linear mixed modeling. R J 2017;2017:378–400.
25.
go back to reference Pittet VEH, Maillard MH, Simonson T et al. Differences in outcomes reported by patients with inflammatory bowel diseases vs their health care professionals. Clin Gastroenterol Hepatol. 2019;17:2050–2059.CrossRef Pittet VEH, Maillard MH, Simonson T et al. Differences in outcomes reported by patients with inflammatory bowel diseases vs their health care professionals. Clin Gastroenterol Hepatol. 2019;17:2050–2059.CrossRef
26.
go back to reference Shafer LA, Walker JR, Chhibba T et al. Independent validation of a self-report version of the IBD disability index (IBDDI) in a population-based cohort of IBD patients. Inflamm Bowel Dis. 2018;24:766–774.CrossRef Shafer LA, Walker JR, Chhibba T et al. Independent validation of a self-report version of the IBD disability index (IBDDI) in a population-based cohort of IBD patients. Inflamm Bowel Dis. 2018;24:766–774.CrossRef
27.
go back to reference Grunert PC, Reuken PA, Stallhofer J, et al. Inflammatory bowel disease in the COVID-19 pandemic—The patients' perspective. J Crohns Colitis. 2020;14:1702–1708.CrossRef Grunert PC, Reuken PA, Stallhofer J, et al. Inflammatory bowel disease in the COVID-19 pandemic—The patients' perspective. J Crohns Colitis. 2020;14:1702–1708.CrossRef
28.
go back to reference D’Amico F, Rahier JF, Leone S et al. Views of patients with inflammatory bowel disease on the COVID-19 pandemic: A global survey. Lancet Gastroenterol Hepatol. 2020;5:631–632.CrossRef D’Amico F, Rahier JF, Leone S et al. Views of patients with inflammatory bowel disease on the COVID-19 pandemic: A global survey. Lancet Gastroenterol Hepatol. 2020;5:631–632.CrossRef
29.
go back to reference Jones JL, Nguyen GC, Benchimol EI et al. The impact of inflammatory bowel disease in Canada 2018: quality of life. J Can Assoc Gastroenterol. 2019;2:S42–S48.CrossRef Jones JL, Nguyen GC, Benchimol EI et al. The impact of inflammatory bowel disease in Canada 2018: quality of life. J Can Assoc Gastroenterol. 2019;2:S42–S48.CrossRef
30.
go back to reference Taxonera C, Alba C, Olivares D, et al. Innovation in IBD care during the COVID-19 pandemic: Results of a cross-sectional survey on patient-reported experience measures. Inflamm Bowel Dis. 2021;27:864–869.CrossRef Taxonera C, Alba C, Olivares D, et al. Innovation in IBD care during the COVID-19 pandemic: Results of a cross-sectional survey on patient-reported experience measures. Inflamm Bowel Dis. 2021;27:864–869.CrossRef
31.
go back to reference George LA, Cross RK. Remote monitoring and telemedicine in IBD: Are we there yet? Curr Gastroenterol Rep. 2020;22:12.CrossRef George LA, Cross RK. Remote monitoring and telemedicine in IBD: Are we there yet? Curr Gastroenterol Rep. 2020;22:12.CrossRef
32.
go back to reference Azzam NA, Aljebreen A, Almuhareb A et al. Disability and quality of life before and during the COVID-19 outbreak: A cross-sectional study in inflammatory bowel disease patients. Saudi J Gastroenterol. 2020;26:256–262.CrossRef Azzam NA, Aljebreen A, Almuhareb A et al. Disability and quality of life before and during the COVID-19 outbreak: A cross-sectional study in inflammatory bowel disease patients. Saudi J Gastroenterol. 2020;26:256–262.CrossRef
33.
go back to reference Yu M, Ye Z, Chen Y et al. Questionnaire assessment helps the self-management of patients with inflammatory bowel disease during the outbreak of Coronavirus disease 2019. Aging (Albany NY). 2020;12:12468–12478.CrossRef Yu M, Ye Z, Chen Y et al. Questionnaire assessment helps the self-management of patients with inflammatory bowel disease during the outbreak of Coronavirus disease 2019. Aging (Albany NY). 2020;12:12468–12478.CrossRef
34.
go back to reference Pulvirenti F, Cinetto F, Milito C et al. Health-related quality of life in common variable immunodeficiency italian patients switched to remote assistance during the COVID-19 pandemic. J Allergy Clin Immunol Pract. 2020;8:1894-1899 e1892.CrossRef Pulvirenti F, Cinetto F, Milito C et al. Health-related quality of life in common variable immunodeficiency italian patients switched to remote assistance during the COVID-19 pandemic. J Allergy Clin Immunol Pract. 2020;8:1894-1899 e1892.CrossRef
Metadata
Title
Impact of the Coronavirus Disease Pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease
Authors
Emma Paulides
Annelieke Pasma
Nicole S. Erler
Rachel L. A. van Eijk
Annemarie C. de Vries
C. Janneke van der Woude
Publication date
28-06-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-07118-8

Other articles of this Issue 7/2022

Digestive Diseases and Sciences 7/2022 Go to the issue